FDA reviews Merck & Co’s Keytruda in new ‘tumour agnostic’ use

FDA reviews Merck & Co’s Keytruda in new ‘tumour agnostic’ use

Submitted by admin on April 8, 2020 - 10:55am
Source: 
Pharmaforum
News Tags: 
Merck
Keytruda
tumor agnostic drugs
biomarkers
Headline: 
FDA reviews Merck & Co’s Keytruda in new ‘tumour agnostic’ use
snippet: 

Merck & Co’s Keytruda cancer immunotherapy could be set for another indication, which could open up for use in all cancer patients whose tumours have a certain genetic biomarker.

Do Not Allow Advertisers to Use My Personal information